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Abstract: The objective of this study was to assess the clinical role
of apparent diffusion coefficient (ADC) analysis in noncystic focal
liver lesion (FLL) classification/characterization.
Six hundred liver magnetic resonances with multi-b (b¼50, 400,
800s/mm2) diffusion-weighted imaging (DwI) were retrospectively
reviewed. Mean ADC was measured in 388 lesions (195 benign and 193
malignant) excluding internal necrotic areas. Cystic benign lesions were
excluded from analysis. Sensitivity and specificity in distinguishing
benign from malignant lesions were calculated. Analysis of variance was
performed to detect differences among subgroups of solid lesions.
Mean ADC of malignant lesions was 0.980103mm2/s, signi-
ficantly (P<0.05) lower than mean ADC of benign lesions
(1.433103mm2/s). Applying an ADC cutoff of 1.066103mm2/s,
specificity and sensitivity for malignancy were respectively 86.6% and
73.6%. Of all lesions, >1/3 (39.5%) presented values lower than
1 103 mm2/s, with 90.0% chance of malignancy. Above
1.5103mm2/s (about 20% of all lesions) chance of malignancy was
9.5%.
DwI cannot assist in noncystic FLL characterization, but can help
in FLL classification in about half the cases.
(Medicine 93(6):e40)
Abbreviations: DwI = diffusion-weighted imaging, FLL = focal
liver lesion.
INTRODUCTION
Magnetic resonance (MR) diffusion-weighted imaging(DwI) is a technique for obtaining good image contrast
by exploiting the properties of water molecule “diffusion”
within tissue; the apparent diffusion coefficient (ADC,
expressed in mm2/s), is a quantitative parameter calculated
by DwI, which combines the effects of capillary perfusion
and mobility of water molecules, thus reflecting the cellu-
larity of tissues and integrity of cell membranes.
To date, DwI is potentially a very useful instrument for
the study of focal liver lesion (FLL) and there is continuous
and growing interest in order to credit its capacity in detecting
and characterizing FLLs, identifying active areas in tumoral
tissues, and predicting response to cancer treatment.1,2
The use of DwI in standard abdomen protocols is becoming
usual, because it is not a time-consuming technique, capable of
detecting FLL in patients with suspected malignant disease.
Moreover, it is feasible also when it is not possible to administrate
gadolinium chelates, as a result of refusal by patients, history of
previous allergic reaction, lack of reliable venous access, and risk
of nephrogenic systemic fibrosis. However, after the first period of
great expectations, whereas the role of DwI in detection has been
already recognized, its function in FLL classification and
characterization still remains under review,3,4 and possible
contribution of ADC measurement in clinical practice has not
been fully clarified yet, especially when facing solid lesion with
indeterminate characteristics on conventional MR imaging. In
fact, as has already been demonstrated,5–10 there is a great overlap
in ADC values among groups of different lesions, in particular
when considering the solid ones.
Given this background, the purpose of our retrospective
study was to evaluate a potential clinical role of ADC
measurement for noncystic FLL classification/characterization.
MATERIALS AND METHODS
Informed written consent for magnetic resonance imaging
(MRI) study and contrast agent administration was obtained
from all patients immediately before the beginning of examina-
tion. This retrospective study was notified to the local ethics
committee and a formal institutional review board approval
was waived because patient anonymity was maintained,
acquisitions were performed using standard abdomen protocol,
and patient care was not impacted. All data and information
derived from study images were under exclusive control of
investigative radiologists.
Patients, FLLs, and Standard of Reference
Six hundreds liver MR examinations consecutively
performed from June 2008 to January 2012 at the radiology
Editor: Hui-Xiong Xu.
Received: April 8, 2014; revised: May 14, 2014; accepted: May 29,
2014.
From the Department of Radiology (MM, MPB, LG), Institute of
Hygiene, Epidemiology and Public Health, University of Brescia, Spedali
Civili di Brescia, Piazzale Spedali Civili 1, Brescia, Department of
Radiology (AV), Ospedale S. Cuore di Gesu, Viale Principe di Napoli,
14/A, Benevento, and Department of Experimental and Clinical Bio-
medical Sciences (FM, SC), Radiodiagnostic Unit no. 2 and Department
of Physics (LNM), University of Florence, Azienda Ospedaliero,
Universitaria Careggi, Largo Brambilla 3, Florence, Italy.
Correspondence: Stefano Colagrande, Department of Experimental and
Clinical Biomedical Sciences, Radiodiagnostic Unit no. 2, University
of Florence, Azienda Ospedaliero-Universitaria Careggi, Largo Bram-
billa 3, Florence 50134, Italy (e-mail: stefano.colagrande@unifi.it).
During the past 2 years, the University Department which Professor
Colagrande is affiliated with has received grants, loans, and has
entered into agreements with various carriers of commercial interests
in the healthcare field: Bayer, Bracco, Novartis, Sanofi Aventis, and
Eli Lilly.
The authors have no conflicts of interest to disclose.
Copyright © 2014 Wolters Kluwer Health | Lippincott Williams &
Wilkins. This is an open access article distributed under the terms of the
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0
License, where it is permissible to download and share the work provided
it is properly cited. The work cannot be changed in any way or used
commercially.
ISSN: 0025-7974
DOI: 10.1097/MD.0000000000000040
1Medicine  Volume 93, Number 6, July 2014 www.md-journal.com
department of Brescia were retrospectively reviewed by two
radiologists, with 15 and 7 years of experience in abdominal
MRI, working at the partnered Department of Radiology of
Florence. The entry criterion for the study choice was the
suspicious or known (from patient history and/or other
previous exams) presence of a FLL, either benign or
malignant. All the examinations were anonymized, exported
from the local picture archiving and communication system
to an external storage device in noncompressed digital
imaging and communications in medicine format, and then
transferred from Brescia Hospital to Florence University.
Both radiologists were blinded to all clinical information.
Of 600 patients examined, 254 patients (116 M and 138 F,
mean age 57 years, age range 21 to 82 years) were enrolled in
the study. A maximum of 5 lesions for each patient were
sampled. Every lesion presented the maximum diameter ³5mm.
Detailed information of used materials is shown in Figure 1.
The final diagnosis for each FLL was based on histo-
logical result, consensus reading by the two above-named
radiologists using unenhanced and dynamic contrast-enhanced
MR images (at least 3 examinations), clinical information, and/
or follow-up imaging evaluations (at least 18 months).
A total of 388 lesions (average diameter 2815mm, 7 to
45 range) were examined, 195 benign and 193 malignant; 155
lesions were located in the left liver lobe whereas the
remaining 233 were located in the right lobe. Among the 195
benign lesions, there were 54 hemangiomas (HE), 25 cysts, 38
hepatic adenomas (HA), 72 focal nodular hyperplasias (FNH),
3 abscesses, and 3 inflammatory pseudotumors. Histological
confirmation was obtained for 54 lesions: 34 HA (6 after
surgical resection and 28 with biopsy), 12 FNH (all with
biopsy), 3 HE, 3 inflammatory pseudotumors (biopsy), and 2
abscesses (aspiration and analysis of liquid of drainage). For
the remaining benign lesions, the diagnosis was achieved based
on distinctive MR findings,11–23 laboratory findings, and
dimensional stability at follow-up exams.
Among the 193 malignant lesions, there were 81 hepato-
cellular carcinomas (HCC), 34 cholangiocarcinomas (CC), 77
metastases (MTX), and only 1 primitive lymphoma. Histological
confirmation was obtained for 86 lesions, respectively: 37 HCC
(12 with biopsy and 25 after resection), 23 CC (15 with biopsy
and 8 after resection), 25 MTX (24 with biopsy and 1 after
resection), and 1 lymphoma (biopsy). For the remaining HCC
and CC, the diagnosis was made in consideration of typical MR
findings,11–23 guidelines of the American Association for the
Study of Liver Diseases guidelines, 24 and increase of tumor
markers (α-feto-protein for HCC and carbohydrate antigen-19.9
for CC). Diagnostic confirmation for neither biopsied nor
resected MTX was obtained by demonstrating dimensional
changes at follow-up controls.
MRI Protocol
All examinations were performed using a 1.5-T MR body
scanner with 18-channel system (Avanto, Siemens Medical
Systems, Erlangen, Germany), maximum gradient strength,
45 mT/m, peak slew rate, 200mT/m/ms, and a 4-channel
phased array body coil. Detailed MR protocol is shown in
Table 1, including the following sequences: axial gradient echo
(GE) T1 weighted (T1w) in out-of-phase, navigator-triggered
axial and coronal turbo spin echo T2 weighted with and
without fat suppression, navigator-triggered axial diffusion-
weighted (Dw) multi-b imaging (b value, single direction¼50,
400, 800 s/mm2), axial GE T1w imaging before and after
intravenous administration of 0.025mmol per kilogram of body
weight of gadoxetic acid disodium (Gadolinium Ethoxybenzyl
Diethylene-Triamine-Pentaacetic Acid, Primovist; Bayer-
Schering, Berlin, Germany).
Parallel imaging integrated technique was used with
acceleration factor 2 applied to all sequences to decrease the
echo train length, improve the quality of images, and reduce
the acquisition time. For sequences acquired using respi-
ratory trigger, we applied the PACE (prospective acquisition
correction) technique for recognition and correction of
motion artifacts. The PACE technique interleaves the
imaging sequence with a navigator sequence. The infor-
mation gained with the navigator is used to synchronize the
600: Assessed for eligibility
346:
Excluded
•    162: No FIIS
•    40: Lesion < 5 mm
•    33: Recent chemoembolization or
      radiofrequency treatments
•    46: Subjected to medical or radiological
      follow-up in less than 6 months
•    30: Dwl not performed
•    35: Dwl performed with different
      protocol
195: Benign
•    54 HE (histology in n = 3)
•    38 HA (n = 34)
•    72 FNH (n = 12)
•    3 abscess (n = 1)
•    3 IP (n = 1)
•    23 Cyst
•    170: No diffuse parenchymal
      abnormalities
•    36: Known liver MTX
•    23: HCV-related cirrhosis
•    12: Steatosis
•    10: HBV-related cirrhosis
•    10: Alcohol-related cirrhosis
•    7: HBV+HCV-related cirrhosis
193: Malignant
•    81 HCC (histology in n = 77)
•    34 CC (n = 23)
•    77 MTX (n = 25)
•    1 Lymphoma (n = 1)
254: Eligible patients (116
M and 138 F, mean age
57 y)
388: Total of lesions
155: Left liver lobe
233: Right liver lobe
FIGURE 1. Flow chart for patient selection. CC¼cholangiocarcinoma, DwI¼diffusion-weighted imaging, FLL¼ focal liver lesion,
FNH¼ focal nodular hyperplasias, HA¼hepatic adenomas, HBV¼hepatitis B virus, HCC¼hepatocellular carcinoma, HCV¼hepatitis
C virus, HE¼hemangiomas, IP¼ in phase, MTX¼metastases.
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measurement with the patient’s breathing cycle and to place
the data acquisition period into the end-expiration phase.
The minimum b-value was set at 50s/mm2 in order to
acquire images with a high contrast-to-noise ratio for optimal
conspicuity of liver lesions while keeping “pseudodiffusion”
by means of perfusion effects low. Trace images were
synthesized for each b-value, and ADC map was calculated
from all diffusion weightings.
The scanner used showed good stability, comparable
with what has already been reported: repeatability and
reproducibility related errors were always <0.8%.25
Image Analysis
For the quantitative analysis of Dw images and for
ADC calculation, we proceeded as follows. The lesion was
detected on images obtained at b¼50s/mm2; a region of
interest (ROI) was manually drawn including the entire
lesion, taking care to avoid either internal necrotic areas or
adjacent vessels. Thereafter, the same ROI was positioned on
the corresponding ADC map and mean ADC value was
found. In case of lesions with maximum diameter >3cm, 3
consecutive measurements were evaluated, taking into
account the mean value. ROIs were drawn taking care to
verify that signal intensity variations (coefficients of varia-
tion inside the ROI) were <5% at every b-value (Figure 2),
especially when the lesion had been located on the left lobe.
For every FLL, a ROI of similar size was also drawn in the
liver parenchyma of the central part of the right lobe (to
avoid cardiac motion artifacts) where data show higher
reproducibility and repeatability, excluding large blood
vessels, biliary vessels, and hepatic borders.25
Statistical Analysis
Both cystic lesions (cyst and abscess groups) and the
single lymphoma were excluded from statistical analysis.
The Levene test was used to display differences in ADC
variances in benign and malignant lesion groups. T-test for
independent groups was adopted to demonstrate differences
between benign and malignant lesions. Then a receiver
operating characteristic (ROC) analysis was performed.
Sensitivity and specificity in distinguishing benign from
malignant lesions were calculated on the whole spectrum of
ADC values, with the corresponding areas under the curve
(AUCs). Afterwards, analysis of variance was performed on
the same variables, to detect significant differences among
the different solid lesion subgroups. When significant differ-
ences were detected, Games-Howell and Bonferroni posthoc
tests were applied, respectively, in case of significant or
nonsignificant differences in subgroup variances revealed by
the Levene test (significance threshold P¼0.05). Descriptive
statistic was also calculated for each subgroup.
Statistical analysis was performed using Statistical
Package for the Social Sciences (SPSS) version 17.0.0 (SPSS
Inc., Chicago, IL).
RESULTS
Mean ADC values of different lesion subgroups are
reported in Table 2. The highest mean ADC values were
found on cysts (among the nonsolid lesions) and inflam-
matory pseudotumors (among the solid ones). The lowest
mean ADC values were found on abscesses (among the
nonsolid lesions) and MTX (among the solid ones). In
accordance with previous studies,5,6,26,27 the mean ADC
value of cirrhotic liver parenchyma (0.933103mm2/s,
standard deviation, SD¼0.055) was significantly lower
(P< 0.05) than that of normal liver parenchyma
(1.085 103mm2/s, SD¼0.064).
Lesion Classification
The ADC mean value of malignant lesions was
0.980 103mm2/s (SD¼0.254), significantly (P<0.05)
lower than the mean ADC value of benign lesions,
1.433 103mm2/s (SD¼0.433) (Figure 3). On performing
ROC analysis, it was found that the area under the curve
with 95% confidence interval (CI) was 0.87 (0.83 to 0.91).
Sensitivity and specificity for malignancy applying different
ADC cutoff values are shown in Table 3. In particular,
applying an ADC cutoff value of 1.066103mm2/s,
specificity and sensitivity for malignancy were 86.6% and
76.3%, respectively. Distributions of malignant and benign
FLLs for different intervals of ADC values are shown in
Table 4. Nearly half of all lesions (42.7%) presented ADC
values between 1.0 and 1.5103mm2/s.
Lesion Characterization
ADC values for each subgroup of lesions are reported
in Figure 4. Among benign lesions both HE and FNH
subgroup showed mean ADC significantly (P<0.05) higher
than that of all malignant subgroups. HA subgroup presented
TABLE 1. MR Protocol Details
Axial GE T1w
in Out-of-Phase
Axial FS
TSE T2w
Coronal
TSE T2w
Axial
Multi-b DwI
Axial
Dynamic FS
GE 3D T1w
TR/TE, ms 131/4.9–131/2.66 2120/79 2120/79 2000/71 5.29/2.57
Field of view, mm, AP-RL 300–420 300–420 300–420 300–420 300–420
Matrix 166 256 166 256 166 256 96 128 176 256
Thickness, mm 5 5 6 5 3
b-values, mm/s2 N/A N/A N/A 50, 400, 800 N/A
Fat suppression method N/A SPAIR N/A SPAIR SPAIR
Acquisition time 17–20” 3–5’ 3–5’ 4–6’ 17–20”
3D¼ three dimension, AP¼ anterior–posterior, DwI¼ diffusion-weighted imaging, GE¼ gradient echo, FS¼ fat saturation, MR¼magnetic
resonance, N/A¼ not applicable, RL¼ right–left, SD¼ standard deviation, SPAIR¼ spectral attenuated inversion recovery, T1w¼T1 weighted,
T2w¼T2 weighted, TE¼ echo time, TR¼ repetition time, TSE¼ turbo spin echo.
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mean ADC values significantly lower than HE; besides, a
significant difference was also found between HA and the
MTX subgroup. No significant differences in mean ADC
were demonstrated among various MTX, CC, and HCC
subgroups.
DISCUSSION
Our study demonstrates that ADC quantification can
help to correctly classify a noncystic FLL as benign or
malignant in about half the cases.
Many papers described an attempt to discriminate
malignant from benign lesions and to characterize them by
the means of ADC value.5–10 However, most of them
A B
C D
FIGURE 2. Image analysis process. The lesion (peripheral cholangiocellular carcinoma) appears hypointense on unenhanced T1w
image (A) and presents heterogeneous enhancement on dynamic postcontrast scan (B, equilibrium phase). ROI (white dashed line)
is manually drawn on DwI obtained at b¼50mm/s2 (C) including the entire lesion, and the same ROI is positioned on the
corresponding ADC map (D) to calculate mean ADC value.
TABLE 2. Mean ADC Values of Different Lesion Subgroups.
Mean ADC Value of Cirrhotic Liver Parenchyma
(0.933 103mm2/s, SD¼0.055) was Significantly Lower
(P<0.05) than that of Normal Liver Parenchyma
(1.085 103 mm2/s, SD¼0.064)
Focal Liver Lesion Mean ADC (10–3mm/s2)
Cyst 2.799
HE 1.774
IP 1.471
FNH 1.315
HA 1.129
Normal parenchyma 1.085
HCC 0.975
CC 0.970
Abscess 0.949
MTX 0.947
Cirrhotic parenchyma 0.933
Lymphoma 0.890
ADC¼ apparent diffusion coefficient, CC¼ cholangiocarcinoma,
FNH¼ focal nodular hyperplasias, HA¼ hepatic adenomas,
HCC¼ hepatocellular carcinoma, HE¼ hemangiomas, IP¼ in phase,
MTX¼metastases, SD¼ standard deviation.
2
1
B M
*
Group
AD
C
FIGURE 3. Classification. Box and whisker plots showing ADC
values of benign and malignant FLLs. The horizontal line in
each box is the median of measured values. Despite some
overlap differences, ADC values between benign and malignant
FLL were statistically significant. ADC¼apparent diffusion
coefficient, B¼benign, M¼malignant.
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presented low statistical power due to the limited sample of
lesion analyzed, also including in the analysis lesions such as
cysts and abscesses,6–10 which usually may be quite confi-
dently diagnosed by the use of conventional MR sequences
and/or clinical statement of the patient and do not cause
many problems in differential diagnosis. In addition, cystic
lesions can alter the group analysis results by increasing
differences in ADC value between benign and malignant
lesions.
Our analysis (with exclusion of necrotic areas in ADC)
presented good results in terms of statistically significant
differences in ADC values between malignant and benign
FLLs. Also sensitivity and specificity for the above-described
cutoff values are quite good (Table 3).
In our opinion the best diagnostic performance in
clinical routine would be obtainable by applying a cutoff
value of 1.066103mm2/s, resulting in a specificity and
sensitivity for malignancy of 86.6% and 76.3%, respectively,
although a wide overlap was present between the groups,
confirming the data of several previous papers.5–10 To better
comprehend the extension of this “gray area” and to evaluate
the effective range of clinical application of ADC, we did
not apply a single cutoff value, but we divided all ADC
values into 3 sets (respectively, <1.0, from 1.0 to 1.5,
>1.5103mm2/s) (Table 4). Indeed, we can see that >1/3
(39.5%) presented values <1103mm2/s, with a 90%
chance of malignancy. Most of the lesions (42.7%) presented
ADC values ranging from 1.0 to 1.5103mm2/s and even
if the larger part of them resulted in being benign (56.7%),
chances to recognize a malignant lesion from a benign one
are tough in such a range. Above 1.5103mm2/s (17.8%)
we can classify a lesion as benign, having 9.5% chances of
malignancy. Summarizing, ADC cannot help in classification
of about 43% of all lesions because of the overlap between
values, but in the remaining cases (more than 50%) ADC
measurement should be considered reliable in differentiating
benign from malignant lesions. With respect to surrounding
parenchyma, when a FLL is iso-hypointense on DwI and
presents ADC value <1103mm2/s, it will be most likely
malignant; if a FLL is iso-hyperintense on DwI and presents
ADC value >1.5103mm2/s, it will be very likely benign.
Our results in terms of lesion characterization were poor;
however, we found statistically significant (P<0.05) dif-
ferences in mean ADC values among benign subgroups and
malignant ones, with the exceptions of HA and inflammatory
pseudotumors. Within the benign nodules, HA subgroup
presented mean ADC values significantly lower than HE and
there was a significant difference between HA and MTX
subgroup, while no significant differences in mean ADC were
demonstrated among various malignancy subgroups.
In our statistical analyses we chose not to include the single
case of primitive liver lymphoma because of its single entity.
However, it showed very low ADC value (0.890103mm2/s)
as theoretically expected because of very dense cellularity and
high diffusion restriction. It is a very rare diagnosis, difficult to
find in everyday practice and even literature reports only few
cases28,29: further analysis is needed based on larger number of
case studies to confirm such low ADC values.
The design of our study was simple and both the used Dw
image acquisition and the mean ADC were potentially feasible
in clinical routine. It should be underlined that
b¼0s/mm2 images were not acquired in our multi-b Dw
protocol. The selection of a low b-value >0s/mm2 provides
suppression of large vessels increasing lesion detection rate
and, consequently, reproducibility of ROI positioning. More-
over, calculation of ADC value can be more accurate when
starting with b value¼50–100s/mm2, because of reduction of
perfusion influence on Dw signal.30 We did not consider fitted
ADC and intravoxel incoherent motion (IVIM) theory, because
of the retrospective nature of this study; however, these results
are not dissimilar from those presented in another of our recent
works (prospective and based on IVIM theory parameters and
fitted ADC).31 When including b¼0s/mm2 images in ADC,
these values could be slightly higher (probably around 10%),
because of the larger contribution of perfusional IVIM in
ADC.
In addition, our aim was to investigate the option in using
ADC measurement as a supplemental parameter in clinical
practice so that any time-consuming method in acquisition or
postprocessing would have not been appropriate. Furthermore,
an important point in our study was the number of included
lesions, large enough to draw accurate statistical conclusions
and this is confirmed by narrow AUCs 95% Confidence
Intervals in ROC analysis (never >0.08).
TABLE 3. Sensitivity and Specificity for Malignancy Apply-
ing Different ADC Cutoff Values. Applying a Cutoff Value of
1.066103mm2/s, Specificity and Sensitivity for Malig-
nancy are of 86.6% and 76.3%, Respectively
ADC (x103mm2/s) Sensitivity, % Specificity, %
0.963 57.9 92.7
1.004 66.8 91.5
1.066 76.3 86.6
1.118 82.6 78.7
1.172 86.8 70.1
1.272 91.6 53.0
1.315 92.1 50.0
ADC¼apparent diffusion coefficient.
TABLE 4. Distribution of Malignant and Benign FLLs for Different Intervals of ADC Values
ADC
(x103mm2/s) Malignant Lesions, % Benign Lesions, % All Lesions, % Chance of Malignancy, % Chance of Benignity, %
<1.0 66.3 8.5 39.5 90.0 10.0
1.0–1.5 30.5 56.7 42.7 38.4 61.6
>1.5 3.2 34.8 17.8 9.5 90.5
ADC¼apparent diffusion coefficient.
ã 2014 Lippincott Williams & Wilkins www.md-journal.com | 5
Medicine • DwI-MR in Focal Liver LesionsVolume 93, Number 6, July 2014
Our study has three major limitations: first, it was a
retrospective study so selection biases cannot be excluded
and an overestimation of DwI accuracy in FLL classification
and characterization is likely present, although not critical31;
second, during acquisition of Dw images cardiac motion
artifacts and noise contamination might have distorted ADC
values to a certain degree, in particular those of lesions
located on the left lobe; third, both the ROI drawing and
positioning on ADC map were highly operator-dependent so
problems with reproducibility of the method should be
considered.
In conclusion, our experience confirms that DwI cannot
assist radiologists in the characterization of FLLs, however it
can help them in the classification of more than half the
cases of noncystic FLLs. In addition, an ADC value found to
be <1103mm2/s (ie, in about 40% of the cases)
represents a strong hint of malignancy.
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